Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple Myeloma

Projects should focus on:

Safety and efficacy of elranatamab in the context of real‑world use
Outpatient administration of elranatamab and alternative CRS/ICANS mitigation strategies
Impact of prior treatments (BsAb, ADC) on elranatamab outcomes, and wash‑out period between treatments
Clinical outcomes of elranatamab according to treatment sequencing for RRMM
Collection and assessment of PROs, caregiver burden, and treatment/prophylaxis adherence
Infection patterns, timing, types, and management strategies, including Ig replacement therapy (IV and/or SQ) while on elranatamab treatment
Assessment of elranatamab use and outcomes across patient subgroups under‑represented in clinical trials (e.g., elderly patients, those with renal impairment)
Characterizing clinical and biological determinants of response to elranatamab, including features associated with primary refractoriness, early versus delayed response, and disease relapse, as well as the identification and validation of predictive and response biomarkers